NOTE: MM = millions
Our analysis concludes G1 Therapeutics (GTHX) is materially undervalued because it trades for less than 1 times estimated peak annual revenues of its primary therapy in development, should it be approved by the FDA by 12/31/2020, and only a small fraction of estimated peak annual revenues should additional indications be approved for its flagship therapy (perhaps as early as FY2023).
Our analysis concludes oncology concern G1 Therapeutics is materially undervalued should it submit an NDA for its Trilaciclib to the FDA (anticipated by June 30, 2020). Trilaciclib has already been designated